Yeast-derived β-glucan in combination with anti-tumor monoclonal antibody therapy in cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 4, Issue 2, 2009, Pages 101-109

  Liu, Jingjing ^a   Gunn, Lacey ^a,b   Hansen, Richard ^a   Yan, Jun ^a,b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

glucan; Anti tumor monoclonal antibody; Complement receptor; Complement regulatory proteins; Immunotherapy; Neutrophils

Indexed keywords

BETA GLUCAN; BEVACIZUMAB; CETUXIMAB; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR; DECTIN 1; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 6; LACTOSYLCERAMIDE; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; POLY (1,6) BETA DEXTRO GLUCOPYRANOSYL (1,3) BETA DEXTRO GLUCOPYRANOSE BETA GLUCAN; PROTEIN KINASE SYK; SCAVENGER RECEPTOR; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WHOLE GLUCAN PARTICLES BETA GLUCAN; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; GRANULOCYTE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LUNG NON SMALL CELL CANCER; NEUTROPHIL; NONHUMAN; OVARY CARCINOMA; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BLOOD; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; XENOGRAFT; YEAST;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA-GLUCANS; HEMATOPOIESIS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; YEASTS;

EID: 68949083425     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489209788452858     Document Type: Review

References (97)

1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23: 1147-1157.
2. Durrant, L. G., Parsons, T.: US20080118509A1 (2008).
3. Fasick, J., Panayotatos, N., Tsang, K.Y.: US20080031873A1 (2008).
4. Esslinger, C., Kuenzle, S., Abela, I., Zippelius, A., Jaeger, D., Knuth, A., Nitsch, R.M.D., Moch, H., Goebels, N.: WO2008110372A1 (2008).
5. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311-2319.
6. Zhang H, Richter M, Greene MI. Therapeutic monoclonal antibodies for the ErbB family of receptor tyrosine kinases. Cancer Biol Ther 2003; 2: 122-126.
7. Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003; 30: 3-8.
8. Gelderman KA, Tomlinson SG, Ross D, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 2004; 25: 158-164.
9. Meng R, Smallshaw JE, Pop LM, et al. The evaluation of recombinant, chimeric, tetravalent antihuman CD22 antibodies. Clin Cancer Res 2004; 10: 1274-1281.
10. Li B, Shi S, Qian W, et al. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res 2008; 68: 2400-2408.
11. Senter PD, Schreiber GJ, Hirschberg DL, et al. Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibodyalkaline phosphatase conjugates. Cancer Res 1989; 49: 5789-5792.
12. Hinton PR, Johlfs MG, Xiong JM, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 2004; 279: 6213-6216.
13. Hinton PR, Xiong JM, Johlfs MG, et al. An engineered human IgG1 antibody with longer serum half-life. J Immunol 2006; 176: 346-356.
14. Yan J, Vetvicka V, Xia Y, et al. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J Immunol 1999; 163: 3045-3052.
15. Hong F, Hansen RD, Yan J, et al. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res 2003; 63: 9023-9031.
16. Hong F, Yan J, Baran JT, et al. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol 2004; 173: 797-806.
17. Cheung NK, Modak S. Oral (1→3),(1→4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res 2002; 8: 1217-1223.
18. Cheung NK, Modak F, Vickers A, Knuckles B. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother 2002; 51: 557-564.
19. Modak S, Koehne G, Vickers A, O'Reilly RJ, Cheung NK. Rituximab therapy of lymphoma is enhanced by orally administered (1→3),(1→4)-D-beta-glucan. Leuk Res 2005; 29: 679-683.
20. Li B, Allendorf DJ, Hansen R, et al. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J Immunol 2006; 177: 1661-1669.
21. Yan J, Allendorf DJ, Brandley B. Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer. Expert Opin Biol Ther 2005; 5: 691-702.
22. Thornton BP, Vetvicka V, Pitman M, Goldman RC, Ross GD. Analysis of the sugar specificity and molecular location of the betaglucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol 1996; 156: 1235-1246.
23. Xia Y, Ross GD. Generation of recombinant fragments of CD11b expressing the functional beta-glucan-binding lectin site of CR3 (CD11b/CD18). J Immunol 1999; 162: 7285-7293.
24. Ross GD. Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein. Crit Rev Immunol 2000; 20: 197-222.
25. Yakubenko VP, Lishko VK, Lam SC, Ugarova TP. A molecular basis for integrin alphaMbeta 2 ligand binding promiscuity. J Biol Chem 2002; 277: 48635-48642.
26. Diamond MS, Garcia-Aguilar J, Bickford JK, Corbi AL, Springer TA. The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J Cell Biol 1993; 120: 1031-1043.
27. Diamond MS, Alon R, Parkos CA, Quinn MT, Springer TA. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1). J Cell Biol 1995; 130: 1473-1482.
28. Li B, Allendorf DJ, Hansen R, et al. Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Cancer Res 2007; 67: 7421-7430.
29. Salvador C, Li B, Hansen R, et al. Yeast-derived {beta}-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models. Clin Cancer Res 2008; 14: 1239-1247.
30. Wasser SP, Weis AL. Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: A modern perspective. Crit Rev Immunol 1999; 19: 65-96.
31. Gawronski M, Park JT, Magee AS, Conrad H. Microfibrillar structure of PGG-glucan in aqueous solution as triple-helix aggregates by small angle x-ray scattering. Biopolymers 1999; 50: 569-578.
32. Ensley HE, Tobias B, Pretus HA, et al. NMR spectral analysis of a water-insoluble (1-->3)-beta-D-glucan isolated from Saccharomyces cerevisiae. Carbohydr Res 1994; 258: 307-311.
33. Williams DL, Pretus HA, McNamee RB, et al. Development, physicochemical characterization and preclinical efficacy evaluation of a water soluble glucan sulfate derived from Saccharomyces cerevisiae. Immunopharmacology 1991; 22: 139-155.
34. Nisini R, Torosantucci A, Romagnoli G, et al. beta-Glucan of Candida albicans cell wall causes the subversion of human monocyte differentiation into dendritic cells. J Leukoc Biol 2007; 82: 1136-1142.
35. Li B, Cramer D, Wagner S, et al. Yeast glucan particles activate murine resident macrophages to secrete proinflammatory cytokines via MyD88- and Syk kinase-dependent pathways. Clin Immunol 2007; 124: 170-181.
36. Yan, J.: US20080167268A1 (2008).
37. Yan J, Vetvicka V, Xia Y, Hanikyrova M, Mayadas TN, Ross GD. Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble beta-glucan. Immunopharmacology 2000; 46: 39-54.
38. Dushkin MI, Chiani AF, Vereschagin EI, Schwartz Y. Carboxymethylated beta-1,3-glucan inhibits the binding and degradation of acetylated low density lipoproteins in macrophages in vitro and modulates their plasma clearance in vivo. Cell Biochem Funct 1996; 14: 209-217.
39. Vereschagin EI, van Lambalgen AA, Dushkin MI, et al. Soluble glucan protects against endotoxin shock in the rat: the role of the scavenger receptor. Shock 1998; 9: 193-198.
40. Rice PJ, Kelley JL, Kogan G, et al. Human monocyte scavenger receptors are pattern recognition receptors for (1→3)-beta-Dglucans. J Leukoc Biol 2002; 72: 140-146.
41. Pearson A, Lux A, Krieger M. Expression cloning of dSR-CI, a class C macrophage-specific scavenger receptor from Drosophila melanogaster. Proc Natl Acad Sci USA 1995; 92: 4056-4060.
42. Ariizumi K, Shen GL, Shikano S, et al. Identification of a novel, dendritic cell-associated molecule, dectin-1, by subtractive cDNA cloning. J Biol Chem 2000; 275: 20157-20167.
43. Brown GD, Gordon S. Immune recognition. A new receptor for beta-glucans. Nature 2001; 413: 36-37.
44. Brown GD, Herre J, Williams DL, et al. Dectin-1 mediates the biological effects of beta-glucans. J Exp Med 2003; 197: 1119-1124.
45. Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med 2003; 197: 1107-1117.
46. Rogers NC, Slack EC, Edwards AD, et al. Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity 2005; 22: 507-517.
47. Gross O, Gewies A, Finger K, et al. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 2006; 442: 651-656.
48. Hsu YM, Zhang Y, You Y, et al. The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. Nat Immunol 2007; 8: 198-205.
49. Taylor PR, Tsoni SV, Willment JA, et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol 2007; 8: 31-38.
50. Saijo S, Fujikado N, Furuta T, et al. Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat Immunol 2007; 8: 39-46.
51. LeibundGut-Landmann S, Gross O, Robinson MJ, et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 2007; 8: 630-638.
52. Zimmerman JW, Lindermuth J, Fish PA, et al. A novel carbohydrate-glycosphingolipid interaction between a beta-(1-3)-glucan immunomodulator, PGG-glucan, and lactosylceramide of human leukocytes. J Biol Chem 1998; 273: 22014-22020.
53. Iwabuchi K, Prinetti A, Sonnino S, et al. Involvement of very long fatty acid-containing lactosylceramide in lactosylceramidemediated superoxide generation and migration in neutrophils. Glycoconj J 2008; 25: 357-374.
54. Iwabuchi K, Nagaoka I. Lactosylceramide-enriched glycosphingolipid signaling domain mediates superoxide generation from human neutrophils. Blood 2002; 100: 1454-1464.
55. Sato T, Iwabuchi K, Nagaoka I, et al. Induction of human neutrophil chemotaxis by Candida albicans-derived beta-1,6-long glycoside side-chain-branched beta-glucan. J Leukoc Biol 2006; 80: 204-211.
56. Klein E, Di Renzo L, Yefenof E. Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells. Mol Immunol 1990; 27: 1343-1347.
57. Ross GD, Vetvicka V. CR3 (CD11b, CD18): A phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. Clin Exp Immunol 1993; 92: 181-184.
58. Zhou M, Todd RF, van de Winkel JG, Petty HR. Cocapping of the leukoadhesin molecules complement receptor type 3 and lymphocyte function-associated antigen-1 with Fc gamma receptor III on human neutrophils. Possible role of lectin-like interactions. J Immunol 1993; 150: 3030-3041.
59. Xue W, Kindzelskii AL, Todd RF, Petty HR. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J Immunol 1994; 152: 4630-4640.
60. Cao D, Mizukami IF, Garni-Wagner BA, et al. Human urokinasetype plasminogen activator primes neutrophils for superoxide anion release. Possible roles of complement receptor type 3 and calcium. J Immunol 1995; 154: 1817-1829.
61. Ross GD, Vetvicka V, Yan J, Xia Y, Vetvickova J. Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology 1999; 42: 61-74.
62. Nakayama H, Yoshizaki F, Prinetti A, et al. Lyn-coupled LacCerenriched lipid rafts are required for CD11b/CD18-mediated neutrophil phagocytosis of nonopsonized microorganisms. J Leukoc Biol 2008; 83: 728-741.
63. Ross GD, Thompson RA, Walport MJ, et al. Characterization of patients with an increased susceptibility to bacterial infections and a genetic deficiency of leukocyte membrane complement receptor type 3 and the related membrane antigen LFA-1. Blood 1985; 66: 882-890.
64. Vetvicka V, Thornton BP, Ross GD. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest 1996; 98: 50-61.
65. Xia Y, Vetvicka V, Yan J, Hanikyrova M, Mayadas T, Ross GD. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J Immunol 1999; 162: 2281-2290.
66. Ross GD, Cain JA, Myones BL, Newman SL, Lachmann PJ. Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement 1987; 4: 61-74.
67. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003; 40: 109-123.
68. Macor P, Tedesco F. Complement as effector system in cancer immunotherapy. Immunol Lett 2007; 111: 6-13.
69. Decaussin M, Sartelet H, Robert C, et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGFR1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 1999; 188: 369-377.
70. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59: 728-733.
71. Ferrer FA, Miller LJ, Lindquist R, et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 1999; 54: 567-572.
72. Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 2001; 12: 129-135.
73. Allendorf DJ, Yan J, Ross GD, et al. C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and {beta}-glucan. J Immunol 2005; 174: 7050-7056.
74. Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001; 97: 339-345.
75. Koga Y, Matsuzaki A, Suminoe A, Hattori H, Hara T. Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): A novel mechanism of antitumor effect by neutrophils. Cancer Res 2004; 64: 1037-1043.
76. Lavigne LM, Albina JE, Reichner JS. Beta-glucan is a fungal determinant for adhesion-dependent human neutrophil functions. J Immunol 2006; 177: 8667-8675.
77. Horner H, Frank C, Dechant C, et al. Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity. J Immunol 2007; 179: 337-345.
78. Kushner BH, Cheung NK. Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes. Cancer Res 1991; 51: 4865-4870.
79. Cramer DE, Allendorf DJ, Baran JT, et al. {beta}-Glucan enhances complement-mediated hematopoietic recovery after bone marrow injury. Blood 2006; 107: 835-840.
80. Patchen ML, Vaudrain T, Correira H, Martin T, Reese D. In vitro and in vivo Hematopoietic activities of Betafectin PGG-glucan. Exp Hematol 1998; 26: 1247-1254.
81. Patchen ML, Liang J, Vaudrain T, et al. Mobilization of peripheral blood progenitor cells by Betafectin PGG-Glucan alone and in combination with granulocyte colony-stimulating factor. Stem Cells 1998; 16: 208-217.
82. Cramer DE, Wagner S, Li B, et al. Mobilization of hematopoietic progenitor cells by yeast-derived beta-glucan requires activation of matrix metalloproteinase-9. Stem Cells 2008; 26: 1231-1240.
83. Stein R, Govindan SV, Hayes M, et al. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody. Clin Cancer Res 2005; 11: 2727-2734.
84. Davis ID, Wiseman GA, Lee FT, et al. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immunol 2007; 7: 13.
85. Foon KA, Chakraborty A, John WJ, Sherratt A, Kohler H, Bhattacharya-Chatterjee M. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J Clin Invest 1995; 96: 334-342.
86. Karanikas V, Hwang LA, Pearson J, et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 1997; 100: 2783-2792.
87. Nicholson S, Bomphray CC, Thomas H, et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol Immunother 2004; 53: 809-816.
88. Boscardin SB, Hafalla JC, Masilamani RF, et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med 2006; 203: 599-606.
89. Baran J, Allendorf DJ, Hong F, Ross GD. Oral beta-glucan adjuvant therapy converts nonprotective Th2 response to protective Th1 cell-mediated immune response in mammary tumor-bearing mice. Folia Histochem Cytobiol 2007; 45: 107-114.
90. Bjorge L, Hakulinen J, Wahlstrom T, Matre R, Meri S. Complement regulatory proteins in ovarian malignancies. Int J Cancer 1997; 70: 14-25.
91. Loberg RD, Day LL, Dunn R, Kalikin LM, Pienta KJ. Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 2006; 8: 69-78.
92. Buettner R, Huang M, Gritsko T, et al. Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity. Mol Cancer Res 2007; 5: 823-832.
93. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001; 114: 800-809.
94. Donev RM, Cole DS, Sivasankar B, Hughes TR, Morgan BP. p53 regulates cellular resistance to complement lysis through enhanced expression of CD59. Cancer Res 2006; 66: 2451-2458.
95. Ko EC, Wang X, Ferrone S. Immunotherapy of malignant diseases. Challenges and strategies. Int Arch Allergy Immunol 2003; 132: 294-309.
96. Spiridon CI, Ghetie MA, Uhr J, et al. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 2002; 8: 1720-1730.
97. Dutta T, Spence A, Lampson LA. Robust ability of IFN-gamma to upregulate class II MHC antigen expression in tumor bearing rat brains. J Neurooncol 2003; 64: 31-44.